Development and clinical implementation of a digital system for risk assessments for radiation therapy.

Failure modes and effects analysis (FMEA) Fault tree analysis (FTA) Process throughput Radiation therapy Risk analysis Risk-based quality management

Journal

Zeitschrift fur medizinische Physik
ISSN: 1876-4436
Titre abrégé: Z Med Phys
Pays: Germany
ID NLM: 100886455

Informations de publication

Date de publication:
02 Sep 2023
Historique:
received: 15 02 2023
revised: 08 08 2023
accepted: 09 08 2023
medline: 5 9 2023
pubmed: 5 9 2023
entrez: 4 9 2023
Statut: aheadofprint

Résumé

Before introducing new treatment techniques, an investigation of hazards due to unintentional radiation exposures is a reasonable activity for proactively increasing patient safety. As dedicated software is scarce, we developed a tool for risk assessment to design a quality management program based on best practice methods, i.e., process mapping, failure modes and effects analysis and fault tree analysis. Implemented as a web database application, a single dataset was used to describe the treatment process and its failure modes. The design of the system and dataset allowed failure modes to be represented both visually as fault trees and in a tabular form. Following the commissioning of the software for our department, previously conducted risk assessments were migrated to the new system after being fully re-assessed which revealed a shift in risk priorities. Furthermore, a weighting factor was investigated to bring risk levels of the migrated assessments into perspective. The compensation did not affect high priorities but did re-prioritize in the midrange of the ranking. We conclude that the tool is suitable to conduct multiple risk assessments and concomitantly keep track of the overall quality management activities.

Identifiants

pubmed: 37666699
pii: S0939-3889(23)00092-2
doi: 10.1016/j.zemedi.2023.08.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The inventors with the Department of Radiation Oncology, Universitätsklinikum Erlangen, and IBA Dosimetry GmbH have a patent pending on some functionality of myQA® PROactive.

Auteurs

Dominik Kornek (D)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: dominik.kornek@uk-erlangen.de.

David Menichelli (D)

IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: David.Menichelli@iba-group.com.

Jörg Leske (J)

IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: Joerg.Leske@iba-group.com.

Michael Hofmann (M)

IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: Michael.Hofmann@iba-group.com.

David Antkiewicz (D)

IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: David.Antkiewicz@iba-group.com.

Tobias Brandt (T)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Tobias.Brandt@uk-erlangen.de.

Oliver J Ott (OJ)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Oliver.Ott@uk-erlangen.de.

Michael Lotter (M)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Michael.Lotter@uk-erlangen.de.

Marga Lang-Welzenbach (M)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Marga.Lang-Welzenbach@uk-erlangen.de.

Rainer Fietkau (R)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Rainer.Fietkau@uk-erlangen.de.

Christoph Bert (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Christoph.Bert@uk-erlangen.de.

Classifications MeSH